The American Association for Cancer Research 2025 Annual Meeting (AACR 2025) is set to take place from April 25 to April 30 in Chicago, the United States. Henlius will share three latest preclinical research results from its pipeline programs. The results to be presented include the novel anti-PD-L1/VEGF bispecific antibody HLX37, a novel KAT6A/B inhibitors with best-in-class potential, and a first-in-class ADC linker-payload featuring a highly differentiated killing mechanism. AACR is the oldest and largest scientific organization in the world focused on every aspect of high-quality, innovative cancer research.
Henlius has maintained a differentiated innovation strategy and is committed to drive innovation in antibody technology to accelerate the development of potential "First-in-Class" and "Best-in-Class" molecules into clinical stages. The company has built a pipeline of about 50 molecules, including monoclonal antibodies (mAbs), polyclonal antibodies (pAbs), antibody-drug conjugates (ADCs), and fusion proteins. Meanwhile, Henlius also leverages cutting-edge technologies such as AI to address unmet clinical needs and enhance the translation of innovative achievements.
Details of the abstract are as follows:
Title: A novel anti-PD-L1/VEGF bispecific antibody (HLX37) with immune checkpoint inhibition, anti-angiogenic, and antineoplastic activities
Session Title: Overcoming Checkpoint Inhibition and Tumor Suppression
Form: Abstract and poster
Abstract Number: 7303
Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST
Location: Poster Section 39, Board #18
Title: Discovery of a novel antibody-drug conjugate linker-payload with a distinct killing mechanism via prolonged unfolded protein response activation
Session Title: Drug Design, Synthesis, and Disposition
Form: Abstract and poster
Abstract Number: 5730
Date and Time: April 29, 2025, 2:00 PM-5:00 PM CST
Location: Poster Section 25, Board #1
Title: Identification of novel KAT6A/B inhibitors with enhanced antitumor activity and reduced hematologic toxicity
Session Title: Lead Identification and Optimization
Form: Abstract and poster
Abstract Number: 6976
Date and Time: April 30, 2025, 9:00 AM-12:00 PM CST
Location: Poster Section 25, Board #5